SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.

SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc . (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of Transthyretin Amyloidosis (ATTR). PRESS RELEASE (English) PRESS RELEASE (Spanish)

The release as fetched from its publisher. sombiotech.com ↗